Recent advances in bacteriocin application as antimicrobials

Recent Patents on Anti-Infective Drug Discovery

Volumn 2, Issue 2, 2007, Pages 115-122

  Gillor, Osnat ^a   Ghazaryan, Lusine ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Antibiotic resistance; Bacteriocin; Colicin; Enterocin; Gram; Lacticin; Lactocin; Lantibiotic; Microcin; Mutacin; Negative; Nisin; Pediocin; Positive; Salvaricin

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; BACTERIOCIN; BETA LACTAM ANTIBIOTIC; COLICIN; COUMARIN DERIVATIVE; DEFENSIN; ENTROCIN; GLYCEROL; GLYCOPEPTIDASE; LACTICIN; LACTOCIN; LANTIBIOTIC; LYSOSTAPHIN; MERSACIDIN; MICROCIN; MUTACIN; NISIN; PEDIOCIN; PENICILLIN G; PHEROMONICIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALIVARICIN; UNCLASSIFIED DRUG;

ANIMAL DISEASE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; BACTERIAL INFECTION; CELL PROLIFERATION; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HELICOBACTER INFECTION; HUMAN; NONHUMAN; PATENT; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; TUMOR; VETERINARY MEDICINE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIOCINS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; PATENTS AS TOPIC;

EID: 34250692043     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489107780832613     Document Type: Review

References (118)

1. Riley MA, Wertz JE. Bacteriocins: evolution, ecology, and application. Annu Rev Microbiol 2002; 56: 117-37.
2. Kerr B, Riley MA, Feldman MW, Bohannan BJ. Local dispersal promotes biodiversity in a real-life game of rock-paper-scissors. Nature 2002; 418: 171-74.
3. Kirkup BC, Riley MA. Antibiotic-mediated antagonism leads to a bacterial game of rock-paper-scissors in vivo. Nature 2004; 428: 412-14.
4. Riley MA, Gordon DM. The ecological role of bacteriocins in bacterial competition. Trends Microbiol 1999; 7:129-33.
5. Gordon DM, Riley MA. A theoretical and empirical investigation of the invasion dynamics of colicinogeny. Microbiology 1990; 145 (Pt 3): 655-61.
6. Riley MA. Molecular mechanisms of bacteriocin evolution. Annu Rev Genet 1998; 32: 255-78.
7. Gillor O, Kirkup BC, Riley MA. Colicins and microcins: the next generation antimicrobials. Adv Appl Microbiol 2004; 54: 129-46.
8. Gillor O, Nigro LM, Riley MA. Genetically engineered bacteriocins and their potential as the next generation of antimicrobials. Curr Pharm Des 2005; 11: 1067-45.
9. Bower CK, Parker JE, Higggins AZ, et al. Protein antimicrobial barrier to bacteial adhesion: in vitro and in vivo evaluaution of nisin-treated implamentable materials. Colloids and Surfaces B: Biointerfaces 2002; 25: 81-90.
10. Cleveland J, Montville TJ, Nes IF, Chikindas ML. Bacteriocins: safe, natural antimicrobials for food preservation. Int J Food Microbiol 2001; 71: 1-20.
11. Breukink E. de Kruijff B. The lantibiotic nisin, a special case or not? Biochim Biophys Acta 1999; 1462: 223-34.
12. Tagg JR, Dierksen KP. Bacterial replacement therapy: adapting 'germ warfare' to infection prevention. Trends Biotechnol 2003; 21: 217-23.
13. Gratia A. Sur un remarquable exemple d'antagonisme entre deux souches de coilbacille. Comp. Rend. Soc. Biol. 1925; 93: 1040-41.
14. Smarda J, Smajs D. Colicins - exocellular lethal proteins of Escherichia coli. Folia Microbiologica 1998; 43: 563-82.
15. Braun V, Pilsl H, Gross P. Colicins: structures, modes of action, transfer through membranes, and evolution. Arch Microbiol 1994; 161: 199-206.
16. Papagianni M. Ribosomally synthesized peptides with antimicrobial properties: biosynthesis, structure, function, and applications. Biotechnol Adv 2003; 21: 465-99.
17. van Kraaij C, de Vos WM, Siezen RJ, Kuipers OP. Lantibiotics: biosynthesis, mode of action and applications. Nat Prod Rep 1999; 16: 575-87.
18. Klaenhammer TR. Genetics of bacteriocins produced by lactic acid bacteria. FEMS Microbiol Rev 1993; 12: 39-85.
19. Nes IF, Diep DB, Havarstein LS, Brurberg MB, Eijsink V, Holo H. Biosynthesis of bacteriocins in lactic acid bacteria. Antonie Van Leeuwenhoek, 1996; 70: 113-28.
20. Garneau S, Martin NI, Vederas JC. Two-peptide bacteriocins produced by lactic acid bacteria. Biochimie 2002; 84: 577-92.
21. Franz CM, van Belkum MJ, Holzapfel WH, Abriouel H, Galvez A. Diversity of enterococcal bacteriocins and their grouping in a new classification scheme. FEMS Microbiol Rev 2007; 31: 293-310.
22. Pag U, Sahl HG. Multiple activities in lantibiotics-models for the design of novel antibiotics? Curr Pharm Des 2002; 8: 815-33.
23. Sahl HG, Bierbaum G. Lantibiotics: biosynthesis and biological activities of uniquely modified peptides from gram-positive bacteria. Ann Rev Microbiol 1998; 52: 41-79.
24. Sahl HG, Jack RW, Bierbaum G. Biosynthesis and biological activities of lantibiotics with unique post-translational modifications. Eur J Biochem 1995; 230: 827-53.
25. Guder A, Wiedemann I, Sahl HG. Posttranslationally modified bacteriocins - the lantibiotics. Biopolymers 2000; 55: 62-73.
26. Nagao JI, Asaduzzaman SM, Aso Y, Okuda K, Nakayama J, Sonomoto K. Lantibiotics: Insight and foresight for new paradigm. J Biosci Bioeng 2006; 102: 139-149.
27. Pag U, Sahl HG. Multiple activities in lantibiotics-models for the design of novel antibiotics? Curr Pharm Des 2002; 8: 815-33.
28. Kuipers OP, Beerthuyzen MM, de Ruyter PG, Luesink EJ, de Vos, WM. Autoregulation of nisin biosynthesis in Lactococcus lactis by signal transduction. J Biol Chem 1995; 270: 27299-304.
29. Quadri LE. Regulation of antimicrobial peptide production by autoinducer-mediated quorum sensing in lactic acid bacteria. Antonie Van Leeuwenhoek 2002; 82: 133-45.
30. Dufour A, Hindre T, Haras D, Le Pennec JP. The biology of lantibiotics from the lacticin 481 group is coming of age. FEMS Microbiol Rev 2007; 31: 134-67.
31. Ryan MP, Meaney WJ, Ross RP, Hill C. Evaluation of lacticin 3147 and a teat seal containing this bacteriocin for inhibition of mastitis pathogens. Appl Environ Microbiol 1998; 64: 2287-90.
32. van Belkum MJ, Stiles ME. Nonlantibiotic antibacterial peptides from lactic acid bacteria. Nat Prod Rep 2000; 17: 323-35.
33. Nes IF, Holo H. Class II antimicrobial peptides from lactic acid bacteria. Biopolymers 2000; 55: 50-61.
34. Riley MA, Wertz JE. Bacteriocins: evolution, ecology, and application. Annu Rev Microbiol 2002; 56: 117-37.
35. Riley MA, Goldstone CM, Wertz JE, Gordon D. A phylogenetic approach to assessing the targets of microbial warfare. J Evol Biol 2003; 16: 690-97.
36. Riley MA, Gordon DM. A survey of Col plasmids in natural isolates of Escherichia coli and an investigation into the stability of Col-plasmid lineages. J Gen Microbiol 1992; 138 (Pt 7): 1345-52.
37. Riley MA, Pinou T, Wertz JE, Tan Y, Valletta CM. Molecular characterization of the klebicin B plasmid of Klebsiella pneumoniae. Plasmid 2001; 45: 209-21.
38. Wertz JE, Riley MA. Chimeric nature of two plasmids of Hafnia alvei encoding the bacteriocins alveicins A and B. J Bacteriol 2004; 186: 1598-605.
39. Gordon DM, Riley MA, Pinou T. Temporal changes in the frequency of colicinogeny in Escherichia coli from house mice. Microbiology 1998; 144 (Pt 8): 2233-40.
40. Braun V, Patzer SI, Hantke K. Ton-dependent colicins and microcins: modular design and evolution. Biochimie 2002; 84: 365-80.
41. Cascales E, Buchanan SK, Duche D, et al. Colicin biology. Microbiol Mol Biol Rev 2007; 71: 158-229.
42. Riley MA, Gordon DM. The ecological role of bacteriocins in bacterial competition. Trends in Microbiology 1999; 7: 129-33.
43. Pons AM, Lanneluc I, Cottenceau G, Sable S. New developments in non-post translationally modified microcins. Biochimie 2002; 84: 531-37.
44. Asensio C, Perez-Diaz JC. A new family of low molecular weight antibiotics from enterobacteria. Biochem Biophys Res Commun 1976; 69: 7-14.
45. Kolter R, Moreno F. Genetics of ribosomally synthesized peptide antibiotics. Ann Rev Microbiol 1992; 46: 141-63.
46. Baquero F, Moreno F. The microcins. FEMS Microbiol Lett 1984; 23: 117-24.
47. Delorenzo V. Isolation and characterization of microcin e-492 from Klebsiella-pneumoniae. Arch Microbiol 1984; 139: 72-75.
48. Gaillard-Gendron S, Vignon D, Cottenceau G, et al. Isolation, purification and partial amino acid sequence of a highly hydrophobic new microcin named microcin L produced by Escherichia coli. FEMS Microbiol Lett 2000; 193: 95-98.
49. World Health Organization; Press 2000.Release WHO/41.http://www.who.int
50. Bakken JS. The fluoroquinolones: how long will their utility last? Scand J Infect Dis 2004; 36: 85-92.
51. Alisky J, Iczkowski K, Rapoport A, Troitsky N. Bacteriophages show promise as antimicrobial agents. J Infect 1998; 36: 5-15.
52. Macfarlane GT, Cummings JH. Probiotics, infection and immunity. Curr Opin Infect Dis 2002; 15: 501-06.
53. Verschuere L, Rombaut G, Sorgeloos P, Verstraete W. Probiotic bacteria as biological control agents in aquaculture. Microbiol Mol Biol Rev 2000; 64: 655-71.
54. Joerger RD. Alternatives to antibiotics: Bacteriocins, antimicrobial peptides and bacteriophages. Poultry Sci 2003; 82: 640-47.
55. Papagianni M. Ribosomally synthesized peptides with antimicrobial properties: biosynthesis, structure, function, and applications. Biotechnol Adv 2003; 21: 465-99.
56. Pag U, Sahl HG. Multiple activities in lantibiotics - models for the design of novel antibiotics? Curr Pharmaceut Des 2002; 8: 815-33.
57. Twomey D, Ross RP, Ryan M, Meaney B, Hill C. Lantibiotics produced by lactic acid bacteria: structure, function and applications. Antonie van Leeuwenhoek International J Gen Molecul Microbiol 2002; 82: 165-85.
58. Lien S, Lowman HB. Therapeutic peptides. Trends Biotechnol 2003; 21: 556-62.
59. Montville TJ, Winkowski K. In Food Microbiology: Fundamentals and Frontiers, M. P. Doyle; L. R. Beuchat, T. J. Montville, eds, American Society for Microbiology Press: Washington, D.C., 1997, pp. 559.
60. Cleveland J, Montville TJ, Nes IF, Chikindas ML. Bacteriocins: safe, natural antimicrobials for food preservation. Intern J Food Microbiol 2001; 71: 1-20.
61. Bower CK, Bothwell MK, McGuire J. Lantibiotics as surface active agents for biomedical applications. Colloids and Surfaces B: Biointerfaces 2001; 22.
62. Post RC. Regulatory perspective of the USDA on the use of antimicrobials and inhibitors in foods. J Food Protec 1996; Suppl. S:78-81.
63. Blackburn, P., Goldstein, B.P., Cook, D.J.: US5804549 (1998).
64. Wang, D., Scholz, M.T.: US20050053593 (2005).
65. Goldstein, B.P.: US5985823 (1999).
66. Goldstein, B.P.: US5910479 (1999).
67. O'Callaghan, R.J.: US20016315996 (2001).
68. Climo, M.W., Archer, G.L., Goldstein, B.P.: US6028051 (1998).
69. Climo, M., Murphy, E., Archer, G.: US20036569830 (2003).
70. Climo, M., Murphy, E., Archer, G.: US20067078377 (2006).
71. Climo, M., Murphy, E., Archer, G.: US20067122514 (2006).
72. Iandolo, J.J., Crupper, S.: US20006043219 (2000).
73. Collins, J., O'Sullivan, G.C., Thornton, G.M., O'Sullivan, M.M.G.: US20047186545 (2004).
74. Hillman JD. Replacement therapy of dental caries. Operative Dentistry Supplement 2001; 6: 39-40.
75. van der Hoeven JS, Rogers AH. Stability of the resident microflora and the bacteriocinogeny of Streptococcus mutans as factors affecting its establishment in specific pathogen-free rats. Infect Immun 1979; 23: 206-13.
76. Beighton D, Hayday H, Walker J. The acquisition of Streptococcus mutans by infant monkeys (Macaca fascicularis) and its relationship to the initiation of dental caries. J Gen Microbiol 1982; 128 (Pt 8): 1881-92.
77. Hillman, J.D.: US20060198793 (2006).
78. Hillman, J.D.: US20067067125 (2006).
79. Hillman, J.D.: US20056964760 (2005).
80. Tagg, J.R., Dierksen, K.P., Upton, M.: US20040232205 (2004).
81. Chilcott, C.N., Tagg, J.R.: US20050079597 (2005).
82. Tagg, J.R., Chilcott, C.N., Burton, J.P.: US20060171901 (2006).
83. Ross, R.P., Rea, M.C., Ryan, M.P., Hill, C.: US20016207411 (2001).
84. Blackburn, P., Polak, J.: US5760026 (1998).
85. Blackburn, P., Polak, J.: USS858962 (1999).
86. Kerr DE, Plaut K, Bramley AJ, et al. Lysostaphin expression in mammary glands confers protecton against staphylococcal infection in transgenic mice. Nat Biotechnol 2001; 19: 66-70.
87. Stern, N.J., Svetoch, E.A., Urakov, N.N., Eruslanov, B.V., Volodina, L.I., Kovalev, Y.N., Kudryavtseva, T.Y., Perelygin, V.V., Pokhilenko, V.D., Levchuk, V.P., Borzenkov, V.N., Svetoch, O.E., Mitsevich, E.V., Mitsevich, I.P.: US20050282753 (2005).
88. Stern, N.J., Svetoch, E.A., Urakov, N.N., Eruslanov, B.V., Volodina, L.I., Kovalev, Y.N., Kudryavtseva, T.Y., Perelygin, V.V., Pokhilenko, V.D., Levchuk, V.P., Borzenkov, V.N., Svetoch, O.E., Mitsevich, E.V., Mitsevich, I.P.: US20060269523 (2006).
89. Eijsink VG, Axelsson L, Diep DB, Havarstein LS, Holo H, Nes IF. Production of class II bacteriocins by lactic acid bacteria; an example of biological warfare and communication. Antonie Van Leeuwenhoek 2002; 81: 639-54.
90. Van Reenen CA, Chikindas ML, Van Zyl WH, Dicks LMT. Characterization and heterologous expression of a class IIa bacteriocin, plantaricin 423 from Lactobacillus plantarum 423, in Saccharomyces cerevisiae. Int J Food Microbiol 2003; 81: 29-40.
91. Barefoot, S.F., Ratnam, P.: US5981473 (1999).
92. Barefoot, S.F., Ratnam, P.: US20016221847 (2001).
93. Ayres, J.W., Sandine, W.E., Weber, G.H.: US5635484 (1997).
94. Rodriguez JM, Martinez MI, Kok J.Pediocin PA-1, a wide-spectrum bacteriocin from lactic acid bacteria. Crit Rev Food Sci Nutr 2002; 42: 91-121.
95. Speelmans, G., Vriesema, A.J., Oolhorst, S.D.E.: US20060165661 (2006).
96. Piva, A., Casadei, G.: US20060233777 (2006).
97. Stern, N.J., Svetoch, E.A., Eruslanov, B.V., Volodina, L.I., Kovalev, Y.N., Kudryavtseva, T.Y., Perelygin, V.V., Pokhilenko, V.D., Levchuk, V.P., Borzenkov, V.N., Svetoch, O.E. Mitsevich, E.V., Mitsevich, I.: US20056153881 (2005).
98. Smarda J, Smajs D. Colicins - exocellular lethal proteins of Escherichia coli. Folia Microbiol (Praha) 1998; 43: 563-82.
99. Dorit, R., Riley, M.A.: US20060229244 (2006).
100. Zakharov, S.D, Cramer, W.A. Colicin crystal structures: pathways and mechanisms for colicin insertion into membranes. Biochim Biophys Acta 2002; 1565: 333-46.
101. Ji G, Beavis RC, Novick RP. Cell density control of staphylococcal virulence mediated by an octapeptide pheromone. Proc Natl Acad Sci USA 1995; 92: 12055-12059.
102. Mayville PGJ, Beavis R, Yang H, Goger M, Novick RP, Muir TW. Structure-activity analysis of synthetic autoinducing thiolactone peptides from Staphylococcus aureus responsible for virulence. Proc Natl Acad Sci USA 1999; 96: 1218-23.
103. Qiu, X.: US20030078207 (2003).
104. Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell 1997; 88: 347-54.
105. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nat 2000; 407: 784-88.
106. Bermudes, D.G., King, I.C., Clairmont, C.A., Lin, S.L., Belcourt, M.: US20050249706 (2005).
107. King, I.C.: US20040229338 (2004).
108. Jordi BJ, Boutaga K, van Heeswijk CM, van Knapen F, Lipman LJ. Sensitivity of Shiga toxin-producing Escherichia coli (STEC) strains for colicins under different experimental conditions. FEMS Microbiol Let 2001; 204: 329-34.
109. Schamberger GP, Diez-Gonzalez, F. Selection of recently isolated colicinogenic Escherichia coli strains inhibitory to Escherichia coli 0157:H7. J Food Protec 2002; 65: 1381-87.
110. Phillips CA. The epidemiology, detection and control of Escherichia coli 0157. J Sci Food Agric 1999; 79: 1367-81.
111. Doyle, M.P., Zhao, T., Harmon, B.G., Brown, C.A.: US5965128 (1999).
112. Yorgey P, Lee J, Kordel J, Vivas E, Warner P, Jebaratnam D, Kolter R. Posttranslational modifications in microcin B17 define an additional class of DNA gyrase inhibitor. Proc Natl Acad Sci USA 1994; 91: 4519-23.
113. Hetz C, Bono MR, Barros LF, Lagos R. Microcin E492, a channel-forming bacteriocin from Klebsiella pneumoniae, induces apoptosis in some human cell lines. Proc Natl Acad Sci USA 2002; 99: 2696-701.
114. Lazebnik Y. Why do regulators of apoptosis look like bacterial toxins? Curr Biol 2001; 11: R767-68.
115. Soto, C., Lagos, R.: US20050159349 (2005).
116. Portrait V, Gendron-Gaillard S, Cottenceau G, Pons A. M. Inhibition of pathogenic Salmonella enteritidis growth mediated by Escherichia coli microcin J25 producing strains. Can J Microbiol 1999; 45: 988-94.
117. Wooley RE, Gibbs PS, Shotts EB. Inhibition of Salmonella typhimurium in the chicken intestinal tract by a transformed avirulent avian Escherichia coli. Avian Dis 1999; 43: 245-50.
118. Wooley, R.E., Shotts, E.B.: US20005043176 (2000).